These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 9175242)

  • 1. Effects of platelets and white blood cells and antiplatelet agent C7E3 (Reopro) on a new test of PAF procoagulant activity of whole blood.
    Despotis GJ; Ikonomakou S; Levine V; Joiner-Maier D; Santoro SA; Joist JH
    Thromb Res; 1997 May; 86(3):205-19. PubMed ID: 9175242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of platelet aggregation by abciximab but not by aspirin can be detected by a new point-of-care test, the hemostatus.
    Coiffic A; Cazes E; Janvier G; Forestier F; Lanza F; Nurden A; Nurden P
    Thromb Res; 1999 Jul; 95(2):83-91. PubMed ID: 10418797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of a new point-of-care test that measures PAF-mediated acceleration of coagulation in cardiac surgical patients.
    Despotis GJ; Levine V; Filos KS; Santoro SA; Joist JH; Spitznagel E; Goodnough LT
    Anesthesiology; 1996 Dec; 85(6):1311-23. PubMed ID: 8968178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time.
    Ammar T; Scudder LE; Coller BS
    Circulation; 1997 Feb; 95(3):614-7. PubMed ID: 9024148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The GP IIb/IIIa inhibitor abciximab (ReoPro) decreases activation and interaction of platelets and leukocytes during in vitro cardiopulmonary bypass simulation.
    Straub A; Wendel HP; Azevedo R; Ziemer G
    Eur J Cardiothorac Surg; 2005 Apr; 27(4):617-21. PubMed ID: 15784360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing platelet and fibrinogen contribution to clot strength using modified thromboelastography in pregnant women.
    Gottumukkala VN; Sharma SK; Philip J
    Anesth Analg; 1999 Dec; 89(6):1453-5. PubMed ID: 10589626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A modified thromboelastographic method for monitoring c7E3 Fab in heparinized patients.
    Greilich PE; Alving BM; O'Neill KL; Chang AS; Reid TJ
    Anesth Analg; 1997 Jan; 84(1):31-8. PubMed ID: 8988995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycoprotein IIb/IIIa receptor antagonists inhibit the development of platelet procoagulant activity.
    Pedicord DL; Thomas BE; Mousa SA; Dicker IB
    Thromb Res; 1998 Jun; 90(6):247-58. PubMed ID: 9700855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effects of c7E3 Fab on thrombus formation and rt-PA-Mediated thrombolysis under flow conditions.
    Huang TC; Jordan RE; Hantgan RR; Alevriadou BR
    Thromb Res; 2001 Jun; 102(5):411-25. PubMed ID: 11395127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis".
    Reverter JC; Béguin S; Kessels H; Kumar R; Hemker HC; Coller BS
    J Clin Invest; 1996 Aug; 98(3):863-74. PubMed ID: 8698879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Greater inhibition of platelet procoagulant activity by antibody-derived glycoprotein IIb--IIIa inhibitors than by peptide and peptidomimetic inhibitors.
    Lages B; Weiss HJ
    Br J Haematol; 2001 Apr; 113(1):65-71. PubMed ID: 11328283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of platelets in platelet-rich plasma by rotablation is speed-dependent and can be inhibited by abciximab (c7E3 Fab; ReoPro).
    Williams MS; Coller BS; Väänänen HJ; Scudder LE; Sharma SK; Marmur JD
    Circulation; 1998 Aug; 98(8):742-8. PubMed ID: 9727543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. European Cooperative Study Group.
    Simoons ML; de Boer MJ; van den Brand MJ; van Miltenburg AJ; Hoorntje JC; Heyndrickx GR; van der Wieken LR; de Bono D; Rutsch W; Schaible TF
    Circulation; 1994 Feb; 89(2):596-603. PubMed ID: 7508826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet aggregatory response to platelet activating factor (PAF), ex vivo, and PAF-acetylhydrolase activity in patients with unstable angina: effect of c7E3 Fab (abciximab) therapy.
    Tselepis AD; Goudevenos JA; Tambaki AP; Michalis L; Stroumbis CS; Tsoukatos DC; Elisaf M; Sideris DA
    Cardiovasc Res; 1999 Jul; 43(1):183-91. PubMed ID: 10536703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative real-time effects on platelet adhesion and aggregation under flowing conditions of in vivo aspirin, heparin, and monoclonal antibody fragment against glycoprotein IIb-IIIa.
    Turner NA; Moake JL; Kamat SG; Schafer AI; Kleiman NS; Jordan R; McIntire LV
    Circulation; 1995 Mar; 91(5):1354-62. PubMed ID: 7867173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy.
    Berkowitz SD; Harrington RA; Rund MM; Tcheng JE
    Circulation; 1997 Feb; 95(4):809-13. PubMed ID: 9054735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro evaluation of c7E3-Fab (ReoPro) eluting polymer-coated coronary stents.
    Baron JH; Gershlick AH; Hogrefe K; Armstrong J; Holt CM; Aggarwal RK; Azrin M; Ezekowitz M; de Bono DP
    Cardiovasc Res; 2000 Jun; 46(3):585-94. PubMed ID: 10912469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of platelet-mediated clot retraction by integrin antagonists.
    Hantgan RR; Mousa SA
    Thromb Res; 1998 Mar; 89(6):271-9. PubMed ID: 9669749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Shear-induced platelet aggregation is inhibited by in vivo infusion of an anti-glycoprotein IIb/IIIa antibody fragment, c7E3 Fab, in patients undergoing coronary angioplasty.
    Konstantopoulos K; Kamat SG; Schafer AI; Bañez EI; Jordan R; Kleiman NS; Hellums JD
    Circulation; 1995 Mar; 91(5):1427-31. PubMed ID: 7867183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro inhibition of factor XIII retards clot formation, reduces clot firmness, and increases fibrinolytic effects in whole blood.
    Jámbor C; Reul V; Schnider TW; Degiacomi P; Metzner H; Korte WC
    Anesth Analg; 2009 Oct; 109(4):1023-8. PubMed ID: 19762725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.